4.5 (277) · $ 9.00 · In stock
Endeavor has concluded patient enrolment in a Phase IIa clinical trial of ENV-101 (taladegib) to treat idiopathic pulmonary fibrosis (IPF).
Endeavor completes patient enrolment in trial of ENV-101
Endeavor completes patient enrolment in trial of ENV-101